APA (7th ed.) Citation

Huang, S., Wan, C., Cao, H., Li, Y., Qian, C., Zhou, H., . . . Xue, S. (2023). Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy. Clinical Case Reports, 11(12), 1. https://doi.org/10.1002/ccr3.8289

Chicago Style (17th ed.) Citation

Huang, Si‐Man, et al. "Preemptive Inotuzumab Ozogamicin Eradicated Measurable Residual Disease in Ph‐negative Acute Lymphoblastic Leukemia Relapsed Post CD19 CART Therapy." Clinical Case Reports 11, no. 12 (2023): 1. https://doi.org/10.1002/ccr3.8289.

MLA (9th ed.) Citation

Huang, Si‐Man, et al. "Preemptive Inotuzumab Ozogamicin Eradicated Measurable Residual Disease in Ph‐negative Acute Lymphoblastic Leukemia Relapsed Post CD19 CART Therapy." Clinical Case Reports, vol. 11, no. 12, 2023, p. 1, https://doi.org/10.1002/ccr3.8289.